| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0024 | LOC101927596 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL0032 | ADAMTS9-AS2 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
| EL0040 | AFAP1-AS1 | non-small cell lung cancer | qPCR etc. | non-small-cell lung cancer tissue | up-regulated | expression | Results showed that patients with high LncRNA AFAP1-AS1 expression lived shorter than those with low LncRNA AFAP1-AS1 expression (Log rank test, P<0.001). Besides, the prognostic value of LncRNA AFAP1-AS1 as well as the clinical features was assessed by Cox regression analysis. The outcome revealed that LncRNA AFAP1-AS1 was closely related to the prognosis of NSCLC | 26463625 | Lnc2Cancer |
| EL0227 | BANCR | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1, NCI-H1975, SK-MES-1 etc.) | down-regulated | expression | Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. | 24655544 | LncRNADisease Lnc2Cancer |
| EL0254 | C1401f132 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
| EL0272 | CASC2 | non-small cell lung cancer | qRT-PCR, overexpression | N/A | down-regulated | expression | CASC2 is involved in the development and progression of NSCLC and shows that CASC2 may be a potential diagnostic and target for new therapies in patients with NSCLC. | 26790438 | |
| EL0276 | CCAT1 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1, NCI-H1975) | up-regulated | interaction | In the present study, a great upregulation of CARLo-5 was observed in cancer tissues compared to their adjacent normal tissues. Meanwhile, patients with high CARLo-5 expression have significantly poorer prognosis than those with low expression. Inhibition of CARLo-5 by siRNA suppressed the proliferation, migration, and invasion in NSCLC cell lines in vitro. In addition, silencing of CARLo-5 reversed the epithelial-mesenchymal transition in NSCLC cell line. | 25129441 | Lnc2Cancer |
| EL0278 | CCAT2 | non-small cell lung cancer | qPCR, knockdown etc. | NSCLC tissue, cell lines (A549, NCI-H1975, NCI-H358, NCI-H1650, NCI-H1299, SK-MES-1 etc.) | up-regulated | regulation | CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. | 24504682 | LncRNADisease Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | non-small cell lung cancer | qPCR, knockdown etc. | cell lines (ABC-1, H1299) | up-regulated | expression | qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. | 26408699 | Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | non-small cell lung cancer | qPCR, Western blot etc. | NSCLC tissue, cell lines (PC9, SPC-A1, NCI-H1975, H1299, H358) | up-regulated | expression | In this study, we reported that ANRIL expression was increased in NSCLC tissues and Its expression level was significantly correlated with TNM stages and tumor size. Moreover, patients with high levels of ANRIL expression had a relatively poor prognosis. In addition, taking advantage of loss of function experiments in NSCLC cells, we found that knockdown of ANRIL expression could impair cell proliferation and induce cell apoptosis both in vitro and vivo. | 25504755 | Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | non-small cell lung cancer | qRT-PCR | 87 NSCLC tissues and three lung cancer cell lines | up-regulated | expression | The expression level of lncRNA ANRIL was higher in NSCLC tissues and lung cancer cells than in adjacent non-tumor tissues and normal human bronchial epithelial cells. Higher expression of lncRNA ANRIL in NSCLC tissues was associated with higher TNM stage and advanced lymph node metastasis. Our results suggested that lncRNA ANRIL was a potential biomarker for NSCLC prognosis. | 25889788 | |
| EL0294 | CES1P1 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL0344 | DLEU2 | non-small cell lung cancer | qRT-PCR, Small interfering RNA (siRNA) transfection, Western blotting, ChIP assays | Pair-matched tumorous and adjacent nontumorous lung tissues from 27 patients, A549 and H1299 | up-regulated | N/A | Histone deacetylases, HDACs inhibitors trichostatin A (TSA) and sodium butyrate upregulated the expression of miR-15a/16-1, among class Ι HDACs subtypes, only knockdown of HDAC3 by specific siRNA increased the hyperacetylation of Dleu2/miR-15a/16-1 promoter region and finally resulted in the upregulation of miR-15a/16-1.overexpression of miR-15a/16-1, which were always deleted or downregulated in lung cancer cells, effectively suppressed cell growth and reduced colony formation | 23867991 | |
| EL0480 | DLGAP2 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future. | 26393913 | Lnc2Cancer |
| EL0490 | FAR2P1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL0500 | FH | non-small cell lung cancer | NSCLC lines 95D and 95C by using high throughput LncRNA chip | 95C, 95D cells and NSCLC tumor tissues | up-regulated | N/A | TATDN1 expression is associated with 95D cells' higher potential of invasion and metastasis | 26943769 | |
| EL0519 | GACAT2 | non-small cell lung cancer | qPCR etc. | NSCLC tissue, cell lines (A549, H157, HEK-293T) | down-regulated | expression | lncRNA HMlincRNA717 expression level was significantly decreased in NSCLC tissues in comparison to adjacent non-tumor tissues. It was also proved that HMlincRNA717 expression was to be associated with NSCLC histological grade, and lymph node metastasis. In addition, survival analysis proved that down-regulated HMlincRNA717 expression was associated with poor overall survival of NSCLC patients. HMlincRNA717 expression was an independent prognostic factor for patients with NSCLC, which might be a potential prognostic biomarker and therapeutic target for NSCLC. | 25674259 | Lnc2Cancer |
| EL0526 | GAS5 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, H1650, H1299, H1975, SK-MES etc.) | down-regulated | N/A | The results revealed that GAS5 expression was down-regulated in cancerous tissues compared to adjacent noncancerous tissues (P < 0.05) and was highly related to tumor size and TNM stage (P < 0.05). This correlation between GAS5 and clinicopathological parameters indicates that GAS5 might function as a tumor suppressor. Furthermore, GAS5 overexpression increased tumor cell growth arrest and induced apoptosis in vitro and in vivo. | 24357161 | Lnc2Cancer |
| EL0528 | GAS6-AS1 | non-small cell lung cancer | qPCR etc. | NSCLC tissue | down-regulated | N/A | In this study, we reported a new lncRNA GAS6-AS1, whose expression was downregulated in tumor tissues in 50 patients with NSCLC compared with those in the adjacent normal tissues. Furthermore, decreased GAS6-AS1 expression was negatively correlated with lymph node metastasis and advanced tumor node metastasis stage. Univariate and multivariate analyses showed that GAS6-AS1 expression served as an independent predictor for overall survival. Altered lncRNA GAS6-AS1 expression might be involved in the development and progression of NSCLC by influencing its host gene and promised to be a potential diagnostic target in patients with NSCLC. | 23979857 | Lnc2Cancer |
| EL0534 | GHSR | non-small cell lung cancer | qPCR, Northern bolt etc. | lung cancer tissue, cell lines (A549, NCI-H1299, Beas-2B etc.) | up-regulated | N/A | Quantitative real-time RT-PCR revealed higher expression of GHSROS in lung cancer tissue compared to adjacent, non-tumour lung tissue. GHSROS function may be dependent on the oncogenic context. The identification of GHSROS, which is expressed in lung cancer and stimulates cell migration in lung cancer cell lines, contributes to the growing number of non-coding RNAs that play a role in the regulation of tumourigenesis and metastatic cancer progression. | 23722988 | Lnc2Cancer |
| EL0544 | GNAS-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL0553 | GUCY1B2 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL0556 | H19 | non-small cell lung cancer | qPCR, Luciferase reporter assays, knockdown, ChIP etc. | NSCLC cell lines (A549, SPCA1) | up-regulated | interaction | The higher expression of H19 was positively correlated with advanced tumor-node-metastasis (TNM) stage and tumor size. Multivariate analyses found that H19 expression could serve as an independent prognostic factor for overall survival of NSCLC. Moreover, chromatin immunoprecipitation (ChIP) assays revealed that H19 was a direct transcriptional target of c-Myc. And, knockdown of H19 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. | 26482621 | Lnc2Cancer |
| EL0556 | H19 | non-small cell lung cancer | RT-PCR, luciferase reporter assay, Chromosome immune coprecipitation (ChIP), disturbing and overexpressing the expression of H19, flow cytometry | NSCLC tissues and cells, the adjacent tissues and normal cells | up-regulated | interaction | lncRNA H19, which is induced by c-Myc, is up-regulated in NSCLC. H19 influences the mitotic progression of NSCLC cell lines. | 26722426 | |
| EL0569 | HIF1A-AS1 | non-small cell lung cancer | qPCR etc. | blood (serum), NSCLC tissue | up-regulated | expression | The levels of XIST (P < 0.05) and HIF1A-AS1 (P < 0.05) were significantly increased in tumor tissues or serum from NSCLC patients as compared to those of control group. Moreover, serum levels of XIST and HIF1A-AS1 were significantly decreased after surgical treatment as compared to pre-operative. | 26339353 | Lnc2Cancer |
| EL0578 | HOTAIR | non-small cell lung cancer | qPCR etc. | NSCLC tissue, cell lines (A549) | up-regulated | N/A | High expression of HOTAIR (tumor/normal ratio >= 2) was detected in 17 patients (22.1%) and was frequently found in patients with advanced stage, lymph node metastasis or lymph-vascular invasion and short disease free interval. Furthermore, brain metastases show significantly higher HOTAIR expression compared to primary cancer tissues. HOTAIR-expressing A549 cells showed induced cell migration and anchorage independent cell growth in vitro. | 23743197 | Lnc2Cancer |
| EL0578 | HOTAIR | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1,NCI-H1975 etc.) | up-regulated | N/A | HOTAIR was highly expressed both in NSCLC samples and cell lines compared with corresponding normal counterparts. HOTAIR upregulation was correlated with NSCLC advanced pathological stage and lymph-node metastasis. Moreover, patients with high levels of HOTAIR expression had a relatively poor prognosis. | 24103700 | Lnc2Cancer |
| EL0578 | HOTAIR | non-small cell lung cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (A549, SK-MES-1) | up-regulated | interaction | In the present study, we demonstrated that HOTAIR was upregulated by hypoxia in NSCLC cells. HOTAIR is a direct target of HIF-1αthrough interaction with putative HREs in the upstream region of HOTAIR in NSCLC cells. Furthermore, HIF-1α knockdown or inhibition could prevent HOTAIR upregulation under hypoxic conditions. Under hypoxic conditions, HOTAIR enhanced cancer cell proliferation, migration, and invasion. | 26088446 | Lnc2Cancer |
| EL0649 | LINC00210 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | up-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL0651 | LINC00261 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | Furthermore, the levels of LINC00261 and TP73-AS1 were significantly differently expressed in subgroups of NSCLC samples.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
| EL0654 | LINC00312 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
| EL0663 | LINC00635 | non-small cell lung cancer | microarray, qRT-PCR | gefitinib-sensitive HCC827 cells and gefitinib-resistant HCC827-8-1 cells | up-regulated | interaction | Silencing of LINC00635-001 alone did not remarkably impact HCC827-8-1 cells, but its combination with gefitinib treatment inhibited Akt activation and sensitized HCC827-8-1 cells to gefitinib-induced cytotoxicity. | 26792719 | |
| EL0667 | LINC00673 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
| EL0675 | LINC00970 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL0709 | LINC01628 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future. | 26393913 | Lnc2Cancer |
| EL0816 | LOC100506974 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL0852 | MAFA-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL0853 | MALAT1 | non-small cell lung cancer | Meta-analysis | non-small cell lung cancer and pancreatic cancer | up-regulated | expression | From subgroup analyses,we present evidence that lncRNA MALAT1 overexpression was an unfavorable prognostic factor for patients' overall survival in non-small cell lung cancer and pancreatic cancer, the pooled HRs (95% CI) were 1.86 (95% CI 1.27-2.73) and 1.78 (95% CI 1.30-2.44), respectively. In conclusion, lncRNA MALAT1 is a potential prognostic factor in human cancers. | 26131129 | |
| EL0853 | MALAT1 | non-small cell lung cancer | N/A | N/A | N/A | expression | In NSCLC metastasizing tumors, MALAT-1 expression is three-fold higher than in non-metastasizing tumors. Furthermore, in patients with stage I disease, MALAT-1 expression is closely correlated with poor prognosis. | 21550244 | LncRNADisease |
| EL0853 | MALAT1 | non-small cell lung cancer | N/A | N/A | N/A | expression | Specific lncRNAs can serve as predictors of tumor outcome, as shown with the expression of the lncRNA MALAT-1 in early-stage non-small cell lung cancer. | 21903344 | LncRNADisease |
| EL0853 | MALAT1 | non-small cell lung cancer | N/A | N/A | N/A | expression | lncRNA-associated disruption to alternative splicing has also been reported in non-small cell lung cancer by virtue of overexpression of MALAT1 | 22817756 | LncRNADisease |
| EL0853 | MALAT1 | non-small cell lung cancer | qPCR etc. | NSCLC tissue | up-regulated | expression | Increased expression of the lncRNA MALAT-1 has been observed in several types of tumors, including metastatic non-small cell lung cancer. | 12970751 | LncRNADisease Lnc2Cancer |
| EL0853 | MALAT1 | non-small cell lung cancer | qPCR etc. | cell lines (A549, plat-E, HTB-58 etc.) | up-regulated | expression | The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. | 22088988 | LncRNADisease Lnc2Cancer |
| EL0853 | MALAT1 | non-small cell lung cancer | qPCR etc. | NSCLC tissue | up-regulated | N/A | MALAT1 was shown to be detectable in the cellular fraction of peripheral human blood, showing different expression levels between cancer patients and cancer-free controls. For the discrimination of NSCLC patients from cancer-free controls a sensitivity of 56% was calculated conditional on a high specificity of 96%. The results of this study indicate that MALAT1 complies with key characteristics of diagnostic biomarkers, i.e., minimal invasiveness, high specificity, and robustness. | 24313945 | Lnc2Cancer |
| EL0853 | MALAT1 | non-small cell lung cancer | qPCR, knockdown, Luciferase reporter assay etc. | NSCLC tissue, cell lines (A549, YTLMC-9) | up-regulated | interaction | MALAT1 is a non-coding RNA overexpressed in non-small cell lung cancer (NSCLC). TDP-43 is a ubiquitously expressed, MALAT1-binding protein implicated in cancer development. TDP-43 overexpression markedly increased MALAT1 transcript level. In summary, these findings demonstrated that MALAT1 expression by regulation of TDP-43 controls cellular growth, migration, and invasion of NSCLCs. | 26265046 | Lnc2Cancer |
| EL0853 | MALAT1 | non-small cell lung cancer | qPCR, Western blot etc. | NSCLC tissue, cell lines (H1915) | up-regulated | expression | We observed that the level of MALAT1 was significantly higher in brain metastasis than that of non brain metastasis samples. The level of MALAT1 was associated with patients' survival. We found that MALAT1 is increased in highly invasive subline of brain metastasis lung cancer cells. Further functional studies indicate that silencing MALAT1 inhibits highly invasive subline of brain metastasis lung cancer cell migration and metastasis by inducing epithelial-mesenchymal transition (EMT). | 25217850 | Lnc2Cancer |
| EL0861 | MEG3 | non-small cell lung cancer | qPCR, Western blot etc. | NSCLC tissue, cell lines (A549, SPC-A1,NCI-H1650, NCI-H358, NCI-H1299, NCI-H1975 etc.) | down-regulated | N/A | MEG3 is significantly down-regulated in NSCLC tissues that could be affected by DNA methylation. Overexpression of MEG3 decreased NSCLC cells proliferation and induced apoptosis.Partially via the activition of p53. Thus, MEG3 may represent a new marker of poor prognosis and is a potential therapeutic target for NSCLC intervention. | 24098911 | Lnc2Cancer |
| EL0950 | MVIH | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1, NCI-H1975, H1299 etc.) | up-regulated | regulation | Long?non-coding?RNA?MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. | 24793017 | LncRNADisease Lnc2Cancer |
| EL0973 | NEAT1 | non-small cell lung cancer | qPCR etc. | lung cancer tissue | up-regulated | expression | The relative level of NEAT1 in NSCLC tissues was significantly elevated as compared to that of the adjacent non-cancer lung tissues. NEAT1 expression was positively correlated with patient age, lymphatic metastasis, vascular invasion and clinical TNM stage. lncRNA NEAT1 may act as a oncogene, which plays an important role in the tumorigenesis and deterioration of human NSCLC. | 25854373 | Lnc2Cancer |
| EL1046 | PANDAR | non-small cell lung cancer | qPCR, Western blot, RIP etc. | lung cancer tissue, cell lines (A549, SPC-A1, NCI-H1299, SK-MES-1 etc.) | down-regulated | interaction | In a cohort of 140 NSCLC patients, decreased PANDAR expression was negatively correlated with greater tumor size (P<0.001) and advanced TNM stage (P=0.002). Moreover, PANDAR could serve as an independent predictor for overall survival in NSCLC (P=0.015). PANDAR-mediated growth regulation is in part due to the transcriptional modulation of Bcl-2 by interacting with NF-YA, thus affecting NSCLC cell apoptosis. | 25719249 | Lnc2Cancer |
| EL1052 | PCAT1 | non-small cell lung cancer | quantitative real-time PCR (QRT-PCR), suppression | non-small cell lung cancer cells | up-regulated | expression | PCAT-1 suppression using PCAT-1 small hairpin RNA (shRNA) with A549 cells inhibited cell proliferation, migration and invasion, while over-expression of PCAT-1 by synthetic plasmid vectors was shown to promote cell proliferation, migration and invasion. Our data suggested that PCAT-1 could play an oncogenic role in NSCLC progression. Silencing PCAT-1 is a potential novel therapeutic approach for lung cancer. | 26770456 | |
| EL1102 | PVT1 | non-small cell lung cancer | knockdown of PVT1 inhibited NSCLC cell proliferation and induced apoptosis both in vitro and in vivo | 105 human NSCLC tissues | up-regulated | N/A | High expression of PVT1 was associated with a higher TNM stage and tumor size | 26908628 | |
| EL1102 | PVT1 | non-small cell lung cancer | qPCR, knockdown etc. | NSCLC tissue, cell lines (A549, H157, HEK-293T) | up-regulated | expression | lncRNA PVT1 expression was significantly upregulated in NSCLC tissues and lung cancer cells. Increased PVT1 expression was significantly correlated with histological grade and lymph node metastasis. In addition, NSCLC patients with PVT1 higher expression have shown significantly poorer overall survival than those with lower PVT1 expression. In vitro assays our results indicated that knockdown of PVT1 inhibited cell proliferation, migration, and invasion. | 25400777 | Lnc2Cancer |
| EL1102 | PVT1 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC lines (A549, H157, H226, H460, HCC827) | up-regulated | expression | Our results indicated that PVT1 expression was significantly increased in NSCLC tissues and cell lines, and its upregulation was associated with advanced T-stage and tumor-node-metastasis (TNM) stage and regional lymph node metastasis. PVT1 expression levels were robust in differentiating NSCLC tissues from controls | 26493997 | Lnc2Cancer |
| EL1114 | RGMB-AS1 | non-small cell lung cancer | microarray, qPCR, Western blot etc. | NSCLC tissue, cell lines (A549 and SPC-A-1) | up-regulated | interaction | LncRNA RGMB-AS1 expression was significantly higher in NSCLC tissues than in adjacent normal tissues, lncRNA RGMB-AS1 and RGMB expression levels in NSCLC tissues were associated with the occurrence of differentiation status, lymph node metastases and TNM stage. Studies also indicated that lncRNA RGMB-AS1and RGMB were inversely correlated. | 26055877 | Lnc2Cancer |
| EL1132 | RP11-1008C21.2 | non-small cell lung cancer | cancer tissues compared to adjacent normal tissues | cancer tissues compared to adjacent normal tissues | down-regulated | N/A | overexpression suppressed the proliferation and migration in NSCLC cell lines in vitro | 26883250 | |
| EL1139 | KCNMB2-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | RP11-385J1.2 and TUBA4B were the most markedly changed of these candidate lncRNAs from 90 NSCLC and normal lung tissue samples. As shown in Fig. 4, RP11-385J1.2 expression in NSCLC was significantly higher than in the adjacent tissues, while TUBA4B expression in NSCLC was significantly lower than in the adjacent tissues. | 25394782 | Lnc2Cancer |
| EL1142 | LINC01627 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future. | 26393913 | Lnc2Cancer |
| EL1157 | AL020996.1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL1160 | AL021707.1 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL1209 | SKP2 | non-small cell lung cancer | qPCR, Western blot etc. | non-small cell lung cancer tissue, NSCLC cell lines(ATCC, Rockville, MD, USA) | differential expression | interaction | These data suggest that the Skp2 may be regulated by Meg3 at post-transcriptional level. Bioinformatics analyses showed that miR-3163 bound to 3'-UTR of Skp2 mRNA in NSCLC cells to inhibit its translation, which was supported by luciferase reporter assay. Meg3 augmented the effects of miR-3163 on Skp2 mRNA, possibly through binding-induced function enhancement, which was supported by the double fluorescent in situ hybridization showing co-localized intracellular Meg3 and miR-3163 signals in NSCLC cells. The miR-3163 levels in NSCLC were not different from in NT, suggesting that the regulation of Skp2 in NSCLC by miR-3163 may require coordination of Meg3 | 26482610 | Lnc2Cancer |
| EL1212 | SLC6A6 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL1221 | SNHG1 | non-small cell lung cancer | qPCR, knockdown etc. | cell lines (NL9980, L9981, A549, H1299, H460, SK-MES-1 etc.) | up-regulated | expression | Noncoding RNA SNHG1 expression was significantly upregulated in lung cancer cells when compared with normal bronchial epithelial cells. In addition, in vitro assays our results indicated that knockdown of SNHG1 inhibited cell proliferation. | 25818744 | Lnc2Cancer |
| EL1236 | SOX2-OT | non-small cell lung cancer | real-time quantitative reverse transcription PCR (qRT-PCR) | lung tumor tissues | up-regulated | N/A | SOX2OT knockdown significantly reduced the colony formation ability of cancer cells | 26846097 | |
| EL1350 | TP53TG1 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL1351 | TP73-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | Furthermore, the levels of LINC00261 and TP73-AS1 were significantly differently expressed in subgroups of NSCLC samples (P = 0.004 and P = 0.03, respetcively). These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
| EL1396 | TUBA4B | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | RP11-385J1.2 and TUBA4B were the most markedly changed of these candidate lncRNAs from 90 NSCLC and normal lung tissue samples. As shown in Fig. 4, RP11-385J1.2 expression in NSCLC was significantly higher than in the adjacent tissues, while TUBA4B expression in NSCLC was significantly lower than in the adjacent tissues. | 25394782 | Lnc2Cancer |
| EL1399 | TUG1 | non-small cell lung cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (A549, SK-MES-1, NCI-H1299 etc.) | down-regulated | regulation | P53-regulated?long?non-coding?RNA?TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. | 24853421 | LncRNADisease Lnc2Cancer |
| EL1420 | LINC01589 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | up-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
| EL1431 | UCA1 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | lung adenocarcinoma tissues, cell lines (PC9, H1975, H460, H23, H1299) | up-regulated | interaction | In our study, UCA1 expression was significantly increased in lung cancer cells and patients with acquired resistance to EGFR-TKIs. Over-expression of UCA1 was significantly associated with a shorter progression-free survival (PFS), in tumors with respond to EGFR-TKIs. | 26160838 | Lnc2Cancer |
| EL1431 | UCA1 | non-small cell lung cancer | qPCR, Western blot, Luciferase reporter assay, RIP etc. | NSCLC and adjacent non-tumor lung tissues, cell lines (A549, H1299, H446, H460, NCIH1650, BEAS-2B) | up-regulated | interaction | UCA1 overexpression enhanced, whereas UCA1 silencing impaired the proliferation and colony formation of NSCLC cells. Moreover, mechanistic investigations showed that UCA1 upregulated the expression of miR-193a-3p target gene ERBB4 through competitively 'spongeing' miR-193a-3p. Overall, we concluded that UCA1 functions as an oncogene in NSCLC, acting mechanistically by upregulating ERBB4 in part through 'spongeing' miR-193a-3p | 26655272 | Lnc2Cancer |
| EL1459 | XIST | non-small cell lung cancer | qPCR etc. | blood (serum), NSCLC tissue | up-regulated | expression | The levels of XIST (P < 0.05) and HIF1A-AS1 (P < 0.05) were significantly increased in tumor tissues or serum from NSCLC patients as compared to those of control group. Moreover, serum levels of XIST and HIF1A-AS1 were significantly decreased after surgical treatment as compared to pre-operative. | 26339353 | Lnc2Cancer |
| EL1462 | XLOC_000371 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
| EL1514 | LOC105373051 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |